494 related articles for article (PubMed ID: 28630191)
1. Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.
Davido B; Fellous L; Lawrence C; Maxime V; Rottman M; Dinh A
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630191
[No Abstract] [Full Text] [Related]
2. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.
Lee M; Abbey T; Biagi M; Wenzler E
Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115227. PubMed ID: 33086177
[TBL] [Abstract][Full Text] [Related]
3. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens.
Wenzler E; Deraedt MF; Harrington AT; Danizger LH
Diagn Microbiol Infect Dis; 2017 Aug; 88(4):352-354. PubMed ID: 28602518
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
Santevecchi BA; Smith TT; MacVane SH
Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
[TBL] [Abstract][Full Text] [Related]
5. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Grupper M; Sutherland C; Nicolau DP
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
[TBL] [Abstract][Full Text] [Related]
6. Successful Treatment of Bacteremia Due to NDM-1-Producing
Hobson CA; Bonacorsi S; Fahd M; Baruchel A; Cointe A; Poey N; Jacquier H; Doit C; Monjault A; Tenaillon O; Birgy A
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530600
[No Abstract] [Full Text] [Related]
7. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.
Shaw E; Rombauts A; Tubau F; Padullés A; Càmara J; Lozano T; Cobo-Sacristán S; Sabe N; Grau I; Rigo-Bonnin R; Dominguez MA; Carratalà J
J Antimicrob Chemother; 2018 Apr; 73(4):1104-1106. PubMed ID: 29272413
[No Abstract] [Full Text] [Related]
8. Management of serious infections caused by metallo β-lactamases with or without OXA-48-like expressing Enterobacterales with aztreonam and ceftazidime/avibactam combination: Dosing strategy for better clinical outcome.
Veeraraghavan B; Bakthavatchalam YD; Soman R; Swaminathan S; Manesh A; Nagvekar V; Nangia V
Indian J Med Microbiol; 2021 Jul; 39(3):286-288. PubMed ID: 33892973
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017.
Stone GG; Seifert H; Nord CE
Int J Antimicrob Agents; 2020 Sep; 56(3):106045. PubMed ID: 32522673
[TBL] [Abstract][Full Text] [Related]
10. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
[TBL] [Abstract][Full Text] [Related]
11. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
[TBL] [Abstract][Full Text] [Related]
12. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
[TBL] [Abstract][Full Text] [Related]
13.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
14.
Monogue ML; Abbo LM; Rosa R; Camargo JF; Martinez O; Bonomo RA; Nicolau DP
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416558
[TBL] [Abstract][Full Text] [Related]
15. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.
MacVane SH; Crandon JL; Nichols WW; Nicolau DP
Antimicrob Agents Chemother; 2014 Nov; 58(11):6913-9. PubMed ID: 25223999
[TBL] [Abstract][Full Text] [Related]
16. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
[TBL] [Abstract][Full Text] [Related]
17. High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.
Aitken SL; Tarrand JJ; Deshpande LM; Tverdek FP; Jones AL; Shelburne SA; Prince RA; Bhatti MM; Rolston KVI; Jones RN; Castanheira M; Chemaly RF
Clin Infect Dis; 2016 Oct; 63(7):954-958. PubMed ID: 27313265
[TBL] [Abstract][Full Text] [Related]
18. Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.
Yasmin M; Fouts DE; Jacobs MR; Haydar H; Marshall SH; White R; D'Souza R; Lodise TP; Rhoads DD; Hujer AM; Rojas LJ; Hoyen C; Perez F; Edwards A; Bonomo RA
Clin Infect Dis; 2020 Aug; 71(4):1095-1098. PubMed ID: 31802119
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
Sader HS; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime-avibactam.
Sanz Herrero F
Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):40-42. PubMed ID: 35488824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
